Kolstoe et al. \[[@bib1]\] offered a contribution to the archive literature by reminding us that what is termed a failure in the common vernacular of clinical trials is potentially a success in that negative results can offer a foundation for what not to do, what does not work, or what is not safe, and thus what to avoid.

When communicating in English, there is always the possibility of having the same word mean two different things. When a clinical trial "fails," it is reasonable for the scientist to look for ways to benefit from the results, thus making it a success of a kind.

From the perspective of a pharmaceutical company, which faces a long development path that averages more than 10 years at a cost of \$2.6 billion \[[@bib2]\], it is easy to understand why a clinical trial that does not meet an important efficacy or safety endpoint would be described quite reasonably as a failure. The same is true for medical device companies, even if the development is perhaps not as lengthy or costly.

Presently, the term "failure" as associated with clinical trials is so heavily ingrained in the vernacular as represented in Ref. \[[@bib3]\] that if there is a desire to truly change that landscape there will need to be evangelists for the cause. Perhaps that is a worthy endeavor, but at best it is a lengthy endeavor and perhaps unlikely to be successful. This terminology is virtually ubiquitous (as anyone can demonstrate by searching for "clinical trial failure" in an online search), and found even in journals of the highest repute \[[@bib4]\].

Unfortunately, the title of the response from Kolstoe et al. implies more than can be defended. Clinical trials are not necessarily successes if they fail to demonstrate efficacy or if they do identify safety concerns. They may be scientific successes, but they are not necessarily so. It is easy to imagine an efficacy test on an inappropriate population, or a trial with so many protocol deviations that the results are no longer of the planned experiment, or a case where a drug is administered improperly and patients suffer. In none of these cases, or many others that we might imagine, would the term "success" be appropriate, no matter how broadly and optimistically some might like to apply that word.

But rather than make too much over the nuances of these words, it is easy to find common ground: There is certainly no substitute for scholarship and professionalism in any scientific endeavor. It is disappointing to read that Kolstoe et al. who serve critical roles on research ethics committees, reported that they routinely review studies that are scientifically inadequate and designed poorly. My hope is that the opportunities for improving clinical trials that are described commonly as failures can be appreciated as described in Ref. \[[@bib3]\], along with the potential that artificial intelligence has to improve the scholarship that will serve as the foundation for future successful clinical trials.
